Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala, Sweden; Linnaeus Center of Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden.
Linnaeus Center of Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden.
Mol Immunol. 2019 Oct;114:353-361. doi: 10.1016/j.molimm.2019.07.032. Epub 2019 Aug 22.
In the alternative pathway (AP) an amplification loop is formed, which is strictly controlled by various fluid-phase and cell-bound regulators resulting in a state of homeostasis. Generation of the "C3b-like" C3(HO) has been described as essential for AP activation, since it conveniently explains how the initial fluid-phase AP convertase of the amplification loop is generated. Also, the AP has a status of being an unspecific pathway despite thorough regulation at different surfaces. During complement attack in pathological conditions and inflammation, large amounts of C3b are formed by the classical/lectin pathway (CP/LP) convertases. After the discovery of LP´s recognition molecules and its tight interaction with the AP, it is increasingly likely that the AP acts in vivo mainly as a powerful amplification mechanism of complement activation that is triggered by previously generated C3b molecules initiated by the binding of specific recognition molecules. Also in many pathological conditions caused by a dysregulated AP amplification loop such as paroxysmal nocturnal hemoglobulinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), C3b is available due to minute LP and CP activation and/or generated by non-complement proteases. Therefore, C3(HO) generation in vivo may be less important for AP activation during specific attack or dysregulated homeostasis, but may be an important ligand for C3 receptors in cell-cell interactions and a source of C3 for the intracellular complement reservoir.
在替代途径 (AP) 中,形成了一个扩增环,该环受到各种液相和细胞结合调节剂的严格控制,从而达到动态平衡的状态。生成“类似 C3b”的 C3(HO) 被描述为 AP 激活所必需的,因为它方便地解释了扩增环中初始液相 AP 转化酶是如何产生的。此外,尽管在不同的表面进行了彻底的调节,AP 仍然具有非特异性途径的状态。在病理条件和炎症期间补体攻击过程中,大量的 C3b 通过经典/凝集素途径 (CP/LP) 转化酶形成。在发现 LP 的识别分子及其与 AP 的紧密相互作用后,越来越有可能的是,AP 在体内主要作为补体激活的强大扩增机制起作用,该机制由先前由特定识别分子结合引发的已生成的 C3b 分子触发。在由 AP 扩增环失调引起的许多病理条件下,例如阵发性夜间血红蛋白尿 (PNH) 和非典型溶血尿毒症综合征 (aHUS),由于 LP 和 CP 的微小激活和/或非补体蛋白酶产生,C3b 是可用的。因此,在特定攻击或失调的动态平衡期间,体内 C3(HO) 的生成对于 AP 激活可能不那么重要,但可能是细胞间相互作用中 C3 受体的重要配体,并且是细胞内补体储备的 C3 来源。